Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715604 | 1.00 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL13871593 | 1.00 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL4101730 | 1.00 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL3157487 | 0.99 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL176646 | 0.99 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3157484 | 0.99 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL176647 | 0.99 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3087440 | 0.97 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL3087438 | 0.97 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL13871584 | 0.95 | CNR2 (0.69) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815790-B2 | Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-14 | — | — | US | disclosed |
| US-9732061-B2 | Cinnoline derivatives useful as CB-1 receptor inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| WO-2017034872-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-9464055-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| WO-2016115013-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | WO | disclosed |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-14 | — | — | US | disclosed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9266835-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| EP-1735286-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-27 | — | — | EP | disclosed |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005095353-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, OPRK1 | CNR1 1/4885CNR2 2/4885 |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885 |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
| US-20170057925-A1 | INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CNR1 1/4885CNR2 3/4885 |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.